Abstract
Drug-induced interstitial lung disease (DILD) is the most common pulmonary adverse event of anticancer drugs. In recent years, the incidence of anticancer DILD has gradually increased with the rapid development of novel anticancer agents. Due to the diverse clinical manifestations and the lack of specific diagnostic criteria, DILD is difficult to diagnose and may even become fatal if not treated properly. Herein, a multidisciplinary group of experts from oncology, respiratory, imaging, pharmacology, pathology, and radiology departments in China has reached the “expert consensus on the diagnosis and treatment of anticancer DILD” after several rounds of a comprehensive investigation. This consensus aims to improve the awareness of clinicians and provide recommendations for the early screening, diagnosis, and treatment of anticancer DILD. This consensus also emphasizes the importance of multidisciplinary collaboration while managing DILD.
Article PDF
References
Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med, 2018,7(10):356
Zhang J, Shen WN, Ji DM, et al. FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors. China Oncol, 2021,31(4):241–249
Xu ZJ. Enhance the importance and knowledge of drug-induced lung injury. Chin J Tubercul Respir Dis (Chinese), 2017,40(10):721–723
Sternbach G. William Osler: narcotic-induced pulmonary edema. J Emerg Med, 1983,1(2):165–167
Rosenow EC 3rd. Drug-induced pulmonary disease. Dis Mon, 1994,40(5):253–310
Li L, Mok H, Jhaveri P, et al. Anticancer therapy and lung injury: molecular mechanisms. Expert Rev Anticancer Ther, 2018,18(10):1041–1057
Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014,15(2):213–222
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013,31(27):3327–3334
Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol, 2017,28(10):2443–2450
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010,362(25):2380–2388
Willemsen AE, Grutters JC, Gerritsen WR, et al. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. Int J Cancer, 2016,138(10): 2312–2321
Gong C, Xiao Q, Li Y, et al. Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome. Oncologist, 2021,26(4):e580–e587
Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res, 2017,9:207–213
Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol, 2017,28(10):2377–2385
Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ, 2020,369: m736
Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest, 2017,152(2):271–281
Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer, 2018,124(2):271–277
Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med, 2022,386(12):1143–1154
Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan (T-DXd) vs. trastuzumab emtansine (TDM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast 03 study. Ann Oncol, 2021,32 (suppl_5):S1283–S1346
Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res, 2012,13(1):39
Delaunois LM. Mechanisms in pulmonary toxicology. Clin Chest Med, 2004,25(1):1–14
Ohta H, Chiba S, Ebina M, et al. Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol, 2012,302(2):L193–L205
Ryrfeldt A. Drug-induced inflammatory responses to the lung. Toxicol Lett, 2000,112–113:171–176
Chatman LA, Morton D, Johnson TO, et al. A strategy for risk management of drug-induced phospholipidosis. Toxicol Pathol, 2009,37(7):997–1005
Sadowska AM, Specenier P, Germonpre P, et al. Antineoplastic therapy-induced pulmonary toxicity. Expert Rev Anticancer Ther, 2013,13(8):997–1006
Kalisz KR, Ramaiya NH, Laukamp KR, et al. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. Radiographics, 2019,39(7):1923–1937
Johkoh T, Lee KS, Nishino M, et al. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest, 2021,159(3):1107–1125
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med, 2018,198(5):e44–e68
Desai SR, Prosch H, Galvin JR. Plain Film and HRCT Diagnosis of Interstitial Lung Disease. In: Hodler J, Kubik-Huch RA, von Schulthess GK, eds. Diseases of the Chest, Breast, Heart and Vessels 2019-2022: Diagnostic and Interventional Imaging. Cham (CH): Springer, 2019:37–45
Akira M, Suganuma N. Acute and subacute chemicalinduced lung injuries: HRCT findings. Eur J Radiol, 2014,83(8):1461–1469
Batra K, Butt Y, Gokaslan T, et al. Pathology and radiology correlation of idiopathic interstitial pneumonias. Hum Pathol, 2018,72:1–17
Zare Mehrjardi M, Kahkouee S, Pourabdollah M. Radiopathological correlation of organizing pneumonia (OP): a pictorial review. Br J Radiol, 2017,90(1071):20160723
Costabel U, Miyazaki Y, Pardo A, et al. Hypersensitivity pneumonitis. Nat Rev Dis Primers, 2020,6(1):65
Kligerman SJ, Franks TJ, Galvin JR. From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia. Radiographics, 2013,33(7):1951–1975
Obadina ET, Torrealba JM, Kanne JP. Acute pulmonary injury: high-resolution CT and histopathological spectrum. Br J Radiol, 2013,86(1027):20120614
Salvatore M, Smith ML. Cross sectional imaging of pulmonary fibrosis translating pathology into radiology. Clin Imaging, 2018,51:332–336
Delaunay M, Cadranel J, Lusque A, et al. Immunecheckpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J, 2017,50(2):1700050
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011,183(6):788–824
American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med, 2002,165(2):277–304
Mattila JT, Fine MJ, Limper AH, et al. Pneumonia. Treatment and diagnosis. Ann Am Thorac Soc, 2014,11(Suppl 4):S189–S192
Latimer KM, Mott TF. Lung cancer: diagnosis, treatment principles, and screening. Am Fam Physician, 2015,91(4):250–256
Ancion A, Lopez R, D’Orio V, et al. Embolie pulmonaire aiguë: paradoxes, jugements et évidences. Rev Med Liege, 2018,73(5–6):319–325
Komiya K, Akaba T, Kozaki Y, et al. A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema. Crit Care, 2017,21(1):228
Tsuchiya N, Griffin L, Yabuuchi H, et al. Imaging findings of pulmonary edema: Part 1. Cardiogenic pulmonary edema and acute respiratory distress syndrome. Acta Radiol, 2020,61(2):184–194
Lind PA, Marks LB, Hardenbergh PH, et al. Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys, 2002,52(1):137–143
Schwaiblmair M, Behr W, Haeckel T, et al. Drug induced interstitial lung disease. Open Respir Med J, 2012,6:63–74
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007,25(15):1960–1966
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol, 2017,35(7):709–717
Shannon VR, Anderson R, Blidner A, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer, 2020,28(12):6145–6157
Pramana A, Browne L, Cox H, et al. Pulmonary fibrosis following breast adjuvant radiation therapy: the modifying effects of endocrine and chemotherapy (PULp FICTion). Int J Radiat Oncol Biol Phys,2015, 93(3): S106
Gemzar® (Gemcitabine) [Prescribing Information]. Lilly USA, 2021. [Available from: https://www.lillymedical.com/en-us/medical-information/oncology/gemzar]
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2018,36(17):1714–1768
National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] V5.0. [Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50]
Chinese Anti-Cancer Association, Committee of Lung Cancer Society. EGFR-TKI ADR Management Chinese Expert Consensus. Chin J Lung Cancer (Chinese), 2019,22(2):57–81
Chinese Society of Clinical Oncology (CSCO) management guideline of toxicities from immune checkpoint inhibitors (Chinese). 2021. [Available from: http://meeting.csco.org.cn/MUser/M/1?returnurl=http://www.csco.org.cn/cn/index.aspx]
National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in Oncology. Management of Immunotherapy-Related Toxicities. 2022. [Available from: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf]
ENHERTU (fam-trastuzumab deruxtecan-nxki) [Prescri-bing Information]. Daiichi-Sankyo 2019. [Available from: https://daiichisankyo.us/prescribinginformation-portlet/getPIContent?productName=Enhertu&inline=true]
Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of druginduced lung injuries. Respir Investig, 2013,51(4):260–277
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 2017,5(1):95
Trinh S, Le A, Gowani S, et al. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines. Asia Pac J Oncol Nurs, 2019,6(2):154–160
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 2014,370(22):2071–2082
King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014,370(22):2083–2092
Dempsey TM, Sangaralingham LR, Yao X, et al. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med, 2019,200(2):168–174
Tian GZ, Wang J, Gao ZC. Drug-induced lung injury. Beijing: People’s Medical Publishing House, 2015.
Yang ZG. Progress of the Treatment of Interstitial Lung Diseases by Chinese Medicine. Shanghai J Tradit Chin Med (Chinese), 2003,37(4):60–64
Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med, 2013,88(8):e13–e64
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
The authors declare that they have no competing interests.
Author Hua-ping DAI is a member of the Editorial Board for Current Medical Science. The paper was handled by other editors and has undergone rigorous peer review process. Author Hua-ping DAI was not involved in the journal’s review of, or decisions related to, this manuscript.
Additional information
This work was supported by grants from CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2021-I2M-1-014) and National Key R & D Program of China (No. 2021YFC2500700).
Fei MA and Hua-ping DAI, on behalf of the Anticancer Drug-induced Interstitial Lung Disease Diagnosis and Treatment Group. The Chinese version of the article entitled “Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease” was initially published in National Medical Journal of China (Chinese): 2022,44(7):693-702. Doi: https://doi.org/10.3760/cma.j.cn112152-20220412-00244
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party materials in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dai, Hp., Ma, F., Ren, Yh. et al. Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. CURR MED SCI 43, 1–12 (2023). https://doi.org/10.1007/s11596-022-2693-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-022-2693-2